[HTML][HTML] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - ncbi.nlm.nih.gov
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
[PDF][PDF] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - pdfs.semanticscholar.org
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
[PDF][PDF] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - researchgate.net
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
KM Wadosky, S Koochekpour - Oncotarget, 2016 - europepmc.org
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - hero.epa.gov
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
[引用][C] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - cir.nii.ac.jp
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - pubmed.ncbi.nlm.nih.gov
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
[HTML][HTML] Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - oncotarget.com
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
KM Wadosky, S Koochekpour - Oncotarget, 2016 - europepmc.org
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
KM Wadosky, S Koochekpour - Oncotarget, 2016 - oncotarget.com
Prostate cancer (PCa) is the most widely diagnosed male cancer in the Western World and
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …
while low-and intermediate-risk PCa patients have a variety of treatment options, metastatic …